Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer

Chemotherapeutic agents and immune checkpoint inhibitors have shown modest efficacy in patients with advanced biliary tract cancers (BTCs). Here the authors report the results of a phase II trial of the anti-PD1 antibody sintilimab plus chemotherapy (gemcitabine and cisplatin) as first-line treatmen...

Full description

Bibliographic Details
Main Authors: Tian-mei Zeng, Guang Yang, Cheng Lou, Wei Wei, Chen-jie Tao, Xi-yun Chen, Qin Han, Zhuo Cheng, Pei-pei Shang, Yu-long Dong, He-ming Xu, Lie-ping Guo, Dong-sheng Chen, Yun-jie Song, Chuang Qi, Wang-long Deng, Zhen-gang Yuan
Format: Article
Language:English
Published: Nature Portfolio 2023-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-37030-w

Internet

https://doi.org/10.1038/s41467-023-37030-w

Similar Items